| FibroGen is a biopharmaceutical company focused on discovering and developing a range of therapeutics. Roxadustat, Co.'s product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity that has received New Drug Application approval in anemia associated with chronic kidney disease in dialysis-dependent patients. Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor, is developed toward Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer and is in a Phase 2 trial for Duchenne muscular dystrophy.Additionally, Co. is developing a biosynthetic corneal implant in China. The FGEN YTD return is shown above.
The YTD Return on the FGEN YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether FGEN YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the FGEN YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.